Codexis
NASDAQ: CDXSRedwood City, US · 1 known investors
Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.
Advanced ManufacturingAI & Machine LearningBiotechDeep Tech
Founders & leadership
GS
Gordon SangsterExecutive
JN
John NicolsExecutive
DS
David SmithNamed on SEC filing
Board
TB
Thomas BaruchBoard director
PC
Pam ChengBoard director
KG
Kathleen GlaubBoard director
BK
Bernard KelleyBoard director
BD
Byron DorganBoard director
PY
Patrick YangBoard director
DW
Dennis WolfBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$50M disclosed across 1 round · 2019
▶$50MraisedJun 2019 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gordon SangsterExecutive Officer
- John NicolsExecutive Officer, Director
- Pam ChengDirector
- Kathleen GlaubDirector
- Bernard KelleyDirector
- Byron DorganDirector
- Thomas BaruchDirector
- Patrick YangDirector
- Dennis WolfDirector
- David SmithDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Codexis went on to found or lead other companies.
Competitors · 3
by search overlapExelixis34 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
LeadIQ19 shared keywordsLeadIQ is a B2B sales prospecting platform that provides contact and account data to enrich CRMs, track buyer role changes, and automate outreach for revenue teams. It integrates with tools like Salesforce, HubSpot, Outreach, and Salesloft, and uses AI to surface high-fit accounts and personalize prospecting.
Contract18 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.
Companies competing with Codexis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Codexis do?
- Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.
- Who are Codexis's investors?
- Codexis's investors include Baruch Future Ventures.
- How much funding has Codexis raised?
- Codexis has disclosed $50M raised across 1 round.
- Where is Codexis headquartered?
- Codexis is headquartered in Redwood City, US.